Trial Profile
A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms REPEAT
- 29 Sep 2022 Status changed from recruiting to discontinued.
- 09 Jul 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 09 Jul 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2020.